The present invention relates to a therapeutic agent, wherein the therapeutic agent is D-Boramine. The therapeutic agent is prepared by mixing L-carnitine tartrate, pyridoxal 5′ phosphate and fumaric acid. D-Boramine, when administered orally or parenterally in therapeutic quantities, is effective for use in the prevention of cancer that arises from mutations to the BRCA1 and BRCA2 genes, i.e., breast and ovarian and the treatment of several types of human diseases including, but not limited to, Antiphospholipid Syndrome, Disseminate Intravascular Coagulation (DIC), infections arising from viruses (including strains of Human Papillomavirus, Herpes Simplex Virus and Simian Virus), tuberculosis (including XDR Tuberculosis) and mycoplasma, Hepatitis A, B and C, MTHFR genetic mutations.